Last reviewed 2026-04-20 · How we verify

ACLIDINIUM

DUAKLIR PRESSAIR combines aclidinium, an anticholinergic, and formoterol, a beta 2 -adrenergic agonist, to provide bronchodilation in COPD.

At a glance

Mechanism of action

DUAKLIR PRESSAIR contains two active ingredients: aclidinium, which blocks muscarinic receptors in the airways to prevent bronchoconstriction, and formoterol, which activates beta 2 -adrenergic receptors to relax bronchial smooth muscle. Both mechanisms work together to improve breathing in patients with COPD.

Approved indications

No approved indications tracked.

Common side effects

• upper respiratory tract infection
• headache
• back pain

Key clinical trials

• Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists
• Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (PHASE3)
• A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants (PHASE1)
• Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
• Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
• A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
• Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
• The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.